15.04.2013 • News

BASF Steps Up Measures Against Patent Infringements

BASF is taking firm steps to stop the distribution of counterfeit versions of its Irgacure 819 photoinitiator product. After repeatedly issuing notifications, BASF has contacted distributors identified as offering counterfeit Irgacure 819 products for sale and legally insisted that they cease marketing and selling these products. One distributor has already committed to withdrawing this product from the market with immediate effect.

Irgacure 819 is a well-known and widely-used photoinitiator that triggers chemical reactions when exposed to UV light which help speed up the drying process for coatings and adhesives. It is currently protected by several patents covering the synthesis process. These are meant to prevent other companies from using this process to produce Irgacure 819 and certain product formulations including aqueous suspensions and mixtures that contain other photoinitiators.

Following an intensive chemical analysis of the counterfeit products, BASF can prove that they were manufactured using BASF's patented synthesis process. According to BASF, these counterfeit versions are all produced in China and sold globally via distributors.

In 2012, BASF invested €1.75 billion in R&D projects and filed around 1,070 patents worldwide. In order to ensure that its customers continue to benefit from this innovation, BASF is committed to fighting all cases of patent infringement.

 

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read